C. Fleurinck

584 citations
28 papers · 129 · h-index 6

Impact in

  • Rheumatology top 10%
    • Spondyloarthritis Studies and Treatments
    • Rheumatoid Arthritis Research and Therapies
  • Immunology
    • Psoriasis: Treatment and Pathogenesis
    • Macrophage Migration Inhibitory Factor

Papers in

  • Rheumatology 23
    • Spondyloarthritis Studies and Treatments 22
    • Rheumatoid Arthritis Research and Therapies 9
    • Systemic Lupus Erythematosus Research 3
  • Immunology 12
    • Psoriasis: Treatment and Pathogenesis 10
Co-authors
Atul Deodhar (12 shared papers)Lianne S. Gensler (14 shared papers)Ute Massow (17 shared papers)Désirée van der Heijde (6 shared papers)Xenofon Baraliakos (11 shared papers)Natasha de Peyrecave (10 shared papers)Maxime Dougados (4 shared papers)Walter P. Maksymowych (5 shared papers)
Journals
Annals of the Rheumatic Diseases (14 papers)RMD Open (3 papers)Lara D. Veeken (2 papers)Arthritis & Rheumatology (1 paper)The Journal of Rheumatology (1 paper)
Partner nations
BelgiumUnited StatesGermany

In The Last Decade

C. Fleurinck

26 papers receiving 128 citations

Peers

C. Fleurinck
Comparison fields: 5 of 21
  • Rheumatology 95
  • Immunology 36
  • Hematology 16
  • Ophthalmology 8
  • Dermatology 6
Replace Iain McInnes with:
Iain McInnes Denmark
Musaab Elmamoun Ireland
Michael Zisapel Israel
Joanne S. Cunha United States
Olga Ziouzina Canada
Mette Holland‐Fischer Denmark
Cruz Fernández-Espartero Spain
Vanesa Cosentino Argentina
Cristina Campos Spain
José Chávez-Corrales Peru
C. Fleurinck relative to Iain McInnes Denmark Iain McInnes's profile →
Citations per field
00.5×10×20×26.5×
Iain McInnes · 1×
Citations per year

Countries citing papers authored by C. Fleurinck

Since Specialization
Citations

This map shows the geographic impact of C. Fleurinck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Fleurinck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Fleurinck more than expected).

Fields of papers citing papers by C. Fleurinck

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Fleurinck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Fleurinck. The network helps show where C. Fleurinck may publish in the future.

Co-authors

The 25 scholars most cited alongside C. Fleurinck, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with C. Fleurinck Line = papers co-authored together C. Fleurinck links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 28 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies
Annals of the Rheumatic Diseases ·Xenofon Baraliakos, Atul Deodhar, Désirée van der Heijde, Marina Magrey, Walter P. Maksymowych, Tetsuya Tomita, Huji Xu, Ute Massow, C. Fleurinck, A.M. Ellis, T. Vaux, Julie Shepherd‐Smith, Alexander Marten, Lianne S. Gensler
202333
2
Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension Study
Arthritis & Rheumatology ·Xenofon Baraliakos, Atul Deodhar, Maxime Dougados, Lianne S. Gensler, Anna Moltó, Sofía Ramiro, Alan Kivitz, Denis Poddubnyy, Marga Oortgiesen, T. Vaux, C. Fleurinck, Julie Shepherd‐Smith, Christine de la Loge, Natasha de Peyrecave, Désirée van der Heijde
202223
3
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials
Annals of the Rheumatic Diseases ·Matthew A. Brown, Martín Rudwaleit, F. van Gaalen, Nigil Haroon, Lianne S. Gensler, C. Fleurinck, Alexander Marten, Ute Massow, Natasha de Peyrecave, T. Vaux, Katy White, Atul Deodhar, Irene van der Horst‐Bruinsma
202415
4
The Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-Fatigue) scale in patients with axial spondyloarthritis: psychometric properties and clinically meaningful thresholds for interpretation
Journal of Patient-Reported Outcomes ·David Cella, Christine de la Loge, Fatoumata Fofana, Shien Guo, Alicia M. Ellis, C. Fleurinck, Ute Massow, Maxime Dougados, Victoria Navarro‐Compán, Jessica A. Walsh
20246
5
Circulating intercellular adhesion molecule-1 and E-selectin in acute ischemic stroke
Journal of Stroke and Cerebrovascular Diseases ·Jan De Bleecker, Ilse Coulier, C. Fleurinck, Jacques De Reuck
19986
6
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies
RMD Open ·Maureen Dubreuil, Victoria Navarro‐Compán, Annelies Boonen, Karl Gaffney, Lianne S. Gensler, Christine de la Loge, T. Vaux, C. Fleurinck, Ute Massow, V. Taieb, Michael F Mørup, Atul Deodhar, Martín Rudwaleit
20245
7
Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension
RMD Open ·Atul Deodhar, Victoria Navarro‐Compán, Denis Poddubnyy, Lianne S. Gensler, Sofía Ramiro, Tetsuya Tomita, Helena Marzo‐Ortega, C. Fleurinck, T. Vaux, Ute Massow, Natasha de Peyrecave, Désirée van der Heijde, Xenofon Baraliakos
20255
8
Trovafloxacin Concentrations in Airway Fluids of Patients with Severe Community-Acquired Pneumonia
Antimicrobial Agents and Chemotherapy ·Renaat Peleman, Vera Van de Velde, Paul Germonpré, C. Fleurinck, M.T. Rosseel, Ruben Pauwels
20004
9
NEO1 and NEO-EXT studies: Long-term safety and exploratory efficacy of repeat avalglucosidase alfa dosing for 5.5 years in late-onset Pompe disease patients
Molecular Genetics and Metabolism ·Mazen M. Dimachkie, Richard J. Barohn, Barry J. Byrne, Özlem Göker-Alpan, Priya S. Kishnani, Shafeeq Ladha, Pascal Laforêt, Eugen Mengel, Loren Peña, Sabrina Sacconi, Volker Straub, Jaya Trivedi, Philip Van Damme, Ans van der Ploeg, John Vissing, Peter Young, Kristina An Haack, C. Fleurinck, Judith Johnson, Kejian Liu
20204
10
OP0019 BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY
Annals of the Rheumatic Diseases ·D. van der Heijde, Xenofon Baraliakos, M. Dougados, M. Brown, D. Poddubnyy, F. Van den Bosch, N. Haroon, H. Xu, T. Tomita, Lianne S. Gensler, Marga Oortgiesen, C. Fleurinck, T. Vaux, A. Marten, Atul Deodhar
20223
11
POS0939 BIMEKIZUMAB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 1, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO‑CONTROLLED STUDY
Annals of the Rheumatic Diseases ·Atul Deodhar, D. van der Heijde, Lianne S. Gensler, H. Xu, Karl Gaffney, H. Dobashi, Walter P. Maksymowych, M. Rudwaleit, M. Magrey, D. Elewaut, Marga Oortgiesen, C. Fleurinck, A.M. Ellis, T. Vaux, J. Smith, Xenofon Baraliakos
20223
12
POS0226 BIMEKIZUMAB LONG-TERM SAFETY AND EFFICACY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY
Annals of the Rheumatic Diseases ·Désirée van der Heijde, Atul Deodhar, Lianne S. Gensler, Denis Poddubnyy, Alan Kivitz, Maxime Dougados, Natasha de Peyrecave, Marga Oortgiesen, T. Vaux, C. Fleurinck, Xenofon Baraliakos
20213
13
POS0806 LONG-TERM SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
Annals of the Rheumatic Diseases ·X. Baraliakos, Ajita Deodhar, D. van der Heijde, F. Van den Bosch, M. Magrey, Walter P. Maksymowych, Tetsuya Tomita, Huji Xu, Ute Massow, C. Fleurinck, T. Vaux, C. Prajapati, Julie Shepherd‐Smith, Alexander Marten, L. S. Gensler
20242
14
POS1104 BIMEKIZUMAB MAINTAINED STRINGENT CLINICAL RESPONSES THROUGH WEEK 52 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2
Annals of the Rheumatic Diseases ·Fabian Proft, Désirée van der Heijde, Xenofon Baraliakos, Joerg Ermann, C. Fleurinck, Ute Massow, Natasha de Peyrecave, V. Taieb, Astrid van Tubergen, Victoria Navarro‐Compán
20232
15
POS0215 LONG-TERM SAFETY AND EFFICACY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 5-YEAR RESULTS FROM A PHASE 2B STUDY AND ITS OPEN-LABEL EXTENSION
Annals of the Rheumatic Diseases ·Atul Deodhar, V. Navarro-Compán, Denis Poddubnyy, Lianne S. Gensler, Sofía Ramiro, T. Tomita, Helena Marzo‐Ortega, C. Fleurinck, T. Vaux, Ute Massow, D. van der Heijde, Xenofon Baraliakos
20242
16
POS0668 LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH BIMEKIZUMAB: POOLED RESULTS FROM PHASE 2B/3 TRIALS
Martín Rudwaleit, Matthew A. Brown, F. van Gaalen, Nigil Haroon, Lianne S. Gensler, C. Fleurinck, Alexander Marten, Ute Massow, Natasha de Peyrecave, T. Vaux, Katy White, Atul Deodhar, Irene van der Horst‐Bruinsma
20232
17
Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE Studies
The Journal of Rheumatology ·Victoria Navarro‐Compán, Martín Rudwaleit, Maureen Dubreuil, Marina Magrey, Helena Marzo‐Ortega, Philip J. Mease, Jessica A. Walsh, Maxime Dougados, Christine de la Loge, C. Fleurinck, Ute Massow, T. Vaux, V. Taieb, Atul Deodhar
20242
18
POS1106 ACHIEVEMENT OF LOW DISEASE ACTIVITY OVER 52 WEEKS IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS ON BIMEKIZUMAB TREATMENT: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2
Annals of the Rheumatic Diseases ·Xenofon Baraliakos, Sofía Ramiro, M. Magrey, Martín Rudwaleit, N. Haroon, C. Fleurinck, Ute Massow, Natasha de Peyrecave, T. Vaux, Helena Marzo‐Ortega, V. Navarro-Compán
20231
19
POS0247 RESOLUTION OF ENTHESITIS AND PERIPHERAL ARTHRITIS WITH BIMEKIZUMAB IN PATIENTS WITH AXIAL SPODYLOARTHRITIS: WEEK 52 RESULTS FROM THE BE MOBILE 1 AND BE MOBILE 2 PHASE 3 STUDIES
Annals of the Rheumatic Diseases ·Sofía Ramiro, Denis Poddubnyy, Philip J. Mease, Clementina López‐Medina, C. Fleurinck, M. Kim, Ute Massow, V. Taieb, Tue Wenzel Kragstrup, Dennis McGonagle
20231
20
AB0938 SAFETY PROFILE OF BIMEKIZUMAB AT WEEK 16 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: RESULTS FROM FOUR PLACEBO-CONTROLLED PHASE 3 STUDIES
Annals of the Rheumatic Diseases ·Denis Poddubnyy, Lianne S. Gensler, Philip J. Mease, Ana‐Maria Orbai, Richard B. Warren, Barbara Ink, Ute Massow, Deepak Assudani, C. Fleurinck, V. Shende, J. Smith, Luke Peterson, Katy White, Robert Landewé
20231

About C. Fleurinck

C. Fleurinck is a scholar working on Rheumatology, Immunology, Ophthalmology, Hematology and Pharmacology, having authored 28 papers that have together received 129 indexed citations. Recurring topics across this work include Spondyloarthritis Studies and Treatments (22 papers), Psoriasis: Treatment and Pathogenesis (10 papers), Rheumatoid Arthritis Research and Therapies (9 papers), Autoimmune and Inflammatory Disorders Research (3 papers), Ocular Diseases and Behçet’s Syndrome (3 papers), Systemic Lupus Erythematosus Research (3 papers), Vitamin C and Antioxidants Research (1 paper) and Colorectal Cancer Treatments and Studies (1 paper). The work is most often cited by research in Rheumatology (95 citations), Immunology (36 citations), Hematology (16 citations), Ophthalmology (8 citations) and Dermatology (6 citations). C. Fleurinck has collaborated with scholars based in Belgium, United States and Germany. Frequent co-authors include Atul Deodhar, Lianne S. Gensler, Ute Massow, Désirée van der Heijde, Xenofon Baraliakos, Natasha de Peyrecave, Maxime Dougados, Walter P. Maksymowych, Tetsuya Tomita and Christine de la Loge. Their work appears in journals such as Annals of the Rheumatic Diseases, RMD Open, Lara D. Veeken, Arthritis & Rheumatology and The Journal of Rheumatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Iain McInnesBreakdown of academic impact, for papers by Musaab ElmamounBreakdown of academic impact, for papers by Michael ZisapelBreakdown of academic impact, for papers by Joanne S. CunhaBreakdown of academic impact, for papers by Olga ZiouzinaBreakdown of academic impact, for papers by Mette Holland‐FischerBreakdown of academic impact, for papers by Cruz Fernández-EsparteroBreakdown of academic impact, for papers by Vanesa CosentinoBreakdown of academic impact, for papers by Cristina CamposBreakdown of academic impact, for papers by José Chávez-Corrales